Селекция ЛАК клетками белка Tag7 человека, клонирование и изучение соответствующего гена

Список литературы

1. Fearon Т. D. and Locksley R.M., «The Instructive Role of Innate Immunity in the Acquired Immune Response», Science, 1996, v.272, April 5, 50−53.
2. Medzhitov R. and Janeway Ch.A., «An ancient system of host defense», Current Opinion in Immunology, 1998, v. 10, 12−15.
3. Medzhitov R. and Janeway Ch.A., «Innate immunity: impact on the adaptive immune response», Current Opinion in Immunology, 1997, v.9, 4−9.
4. Абелев Г. И., «Взаимодействие врожденного и приобретенного иммунитета в защите организма от инфекции», Соросовский образовательный журнал, 1998, п. 2, 52−58.
5. Bendelac A. and Fearon D.T., «Innate Immunity. Innate pathway that control acquired immunity», Current Opinion in Immunology", 1997, v.9, 1−3.
6. Dinarello C.A., «A TH1 -inducing, proinflammatory cytokine and new member of the IL-1 family»., J. Allergy Clin. Immunol., 1999, January, n.103, 11−24.
7. Muzio M., Ni J., Fend P., Dixit V.M., «IRAK (Pelle) Family Member IRAK-2 and MyD88 as Proximal Mediators of IL-1 Signaling», Science, 1997, November 28, v.278, 1612−1615.
8. Yanagata M., Merkie, J.P., and Sanes J.R., «Interspecific comparisons reveal conserved features of the Drosophila Toll protein», Gene, 1994, n. 139, 223 228.
9. Medzhitov R., Preston-Hurlburt P. and Janeway Ch. A., «A human homologue of the Drosophila Toll protein signals activation of adaptive immunity», Nature, 1997, July 24, v.388, 394−397.
10. Taguchi T., Mitcham J.L., Dower S.K., Sims J.E., and Testa J.R., «Chromosomal Localization of TIL, a Gene Encoding a Protein Related to the Drosophila Transmembrane Receptor Toll, to Human Chromosome 4pl4″, Genomics, 1996, n.32, 486−488.
11. Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., and Bazan J.F., „A family of human receptors structurally related to Drosophila Toll“, PNAS, 1998, January, v.95, 588−593.
12. Hultmark D., „Macrophage differentiation marker MyD88 is a member of the Toll/IL-1 receptor family“, 1994, February 28, v.199, n. 1, 144−146.
13. Hardiman G., Jenkins N.A., Copeland N.G., Gilbert D.J., Garcia D.K., Naylor S.L., Kastelein R.A., and Bazan J.F., „Genetic Structure and Chromosomal Mapping of MyD88″, Genomics, 1997, n.45, 332−339.
14. Colaco C., „Why are dendritic cells central to cancer immunotherapy?“, Molecular Medicine Today, 1999, January, 14−17.
15. Liu C.C., Raffi S., Granelli-Piperano A., Trapani J. A, Young J.D., „Perforin and serine esterase gene expression in stimulated human T cells: Kinetics, mitogen requirements and effects of cyclosporin A“, J. Exp. Med., 1989, v.170, 2105−2118.
16. Henkart P.A., „Mechanisms of lymphokine-mediated cytotoxicity“, Annual Rev. Immunol., 1985, v.3, 31−52
17. Jones J., Morgan B.P., „Killing of cells by perforin“, Biochem J., 1991, v.280, 199.
18. Kagi D., Ledermann В., Burki K., Seiler O., Odermatt В., Olsen KJ. Podack ER, Zinkerrnagel RM, Hengartner H: „Cytotoxicity meriated by T cells and natural killer cells is greatly impaired in perforine-deficient mice“, Nature, 1994, n.369, 31−36.
19. Masson D., Tschopp J., „A family of serine esterases in lytic granules of cytotoxic T lymphocytes, Cell, 1987, v.49, 679.
20. Сащенко Jl.П., Лукьянова Т. И., Миркина И. И., Понгор Ш., Гнучев Н.В.,
21. Влияние гранулярных сериновых протеаз и протеинкиназ на цитолитическое действие ЛАК клеток“, Доклады РАН, 1998, 360, 305 309.
22. Shresta S., Maclor D.M., Heusel J.W., Russell J.H., Ley T. J., „Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in susceptible target cells“, Proc. Natl. Acad. Sci USA, 1995, 92, 5679−5683.
23. Shresta S., Goda P., Wesselschimdt R., Ley T.J., „Residual cytotoxicity and granzyme K expression in granzyme A-deficient cytotoxic lymphocytes“, J. Biol. Chem., 1997, 272, 20 236−20 244.
24. Shresta S., Pham Ch., Thomas D.A., Graubert T.A. and Ley T.J., „How do cytotoxic lymphocytes kill their targets ?“, Current Opinion in Immunology, 1998, n.10, 581−587.
25. Hasegawa Y., Bonavida B., „Calcium-independant pathway of TNF-mediated lysis of target cells“, J. Immunol., 1989, v. 142, 2670.
26. Klefstrom J., Vastrik I., Saksela E., Valle J., Eilers M. and Alitalo K., „c-Myc induces cellular susceptibility to the cytotoxic avtion of TNF-a“, EMBO, 1994, v.13, n. 22, 5442−5450.
27. Wang J. and Lenardo M. J., „Molecules involved on cell death and peripheral tolerance“, Current Opinion in Immunology, 1997, n.9, 818−825.
28. Grell M., Wajant H., Zimmermann G. and Scheurich P., „The type 1 receptor (CD 120a) is the high-affinity receptor for soluble tumor necrosis factor“, Proc. Natl. Acad. Sci. USA, 1998, January, v.95, 570−575.
29. Scott D.W., Grdina T., Shi Y., „T cells commit suicide, but B cells are murdered“, J. Immunol., 1996, April 1, v.156, n. 7, 2352−2356.
30. Osborne B.A., „Apoptosis and the maintenance of homeostasis in the immune system“, Current Opinion in Immunology, 1996, n.8, 245−254.
31. Gao Y., Herndon J.M., Zhang H., Griffith T. S., and Ferguson T. A., „Antiinflammatory effect of CD95 Ligand (FASL)-induced apoptosis“, J. Exp. Med., 1998, September, v. 188, n.5, 887−896.
32. Arai H., Gordon D., Nabel G.J., Nabel G. J, „Gene transfer of FAS ligand induces tumor regression in vivo“, Proc. Natl. Acad. Sci. USA, 1997, n. 94, 13 862−13 867.
33. Seino K.I., Kayagaki N., Okumura K., Yagita H., „Antitumor effect of locally produced CD95 ligand“, Nat. Med., 1997, n.3, 165−170.
34. Seino K.I., Kayagaki N., Tsukada N., Fukao K., Yagita H., Okumura K., „Transplantation of CD95 ligand-expressing grafts. Influence of transplantation site and difficulty in protecting alio- and xenografts“, Transplantation, 1997, n. 64, 1050−1054.
35. Nagata S., „Apoptosis by Death Factor“, Cell, 1997, February 7, v.88, 355−365.
36. Devy O., „Antibiotic proteins of polymorphonuclear leukocytes“, Eur. J. Haematol. 1996 May, 56 (5), 263−77
37. Lehrer R.I., Ganz T., „Defensins: endogenous antibiotic peptides from human leukocytes“, Ciba Found Symp., 1992, n. 171, 276−293.
38. Lillard J.W., Boyaka P.N., Chertov O., Oppenheim J.J., McGhee J.R., „Mechanisms for induction of acquired host immunity by neutrophil peptide defensins“. Proc Natl Acad Sci U S A, 1999, January 19, 96 (2), 651−6.
39. Biron C.A., „Role of early cytokines, including alpha and beta interferons IFN-alpha/beta), in innate and adaptive immune responses to viral infections.“, Semin. Immunol., 1998, October, 10 (5), 383−90.
40. Ross E.M. and Caligiuri M.A., „Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response“, Blood, 1997, February 1, v.89, n. 3, 910−918.
41. Fehniger T.A., Shah M.H., Turner M.J., VanDeusen J.B., Whitman S.P., Cooper M.A., Suzuki K., Wechser M., Goodsaid F., Caligiuri
42. M.A.,"Differential Cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response“, J. Immunol., 1999, April 15, 162 (8), 4511−4520.
43. Rosenberg S.A., „Immunotherapy and gene therapy of cancer“, Cancer Research (Suppl.), 1991, September 15, 51, 5074−5079.
44. Ortaldo J.L., Mason A., Overton R., „Lymphokine-activated killer cells. Analysis of progenitors and effectors“, J. Exp. Med, 1986, v. 164, 1193.
45. Ballas Z.K., Rasmussen W., van Otegham G.K., „Lymphokine-activated killer (LAK) cells. Delineation of distinct murine LAK precursor subpopulation“, J. Immunol., 1987, v. 138, 1647.
46. Phillips J.H., Lanier L.L., „Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T-lymphocytes to cytolysis“, J. Exp. Med., 1986, v.164, 814.
47. Pardoll D.M., „Cancer vaccines“, Nature Medicine Vaccine Supplement, 1998, May, v.4, n.5, 525−531.
48. Hart I., and Colaco C., „Fusion induces tumor rejection“, Nature, 1997, 388, 627−628.
49. Banchereau J., and Steinman R.M., „Dendritic cells and the control of immunity“, Nature, 1998, 392, 245−252.
50. Bakkar A.B.H., „Generation of anti-melanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro“, Cancer Res., 1995, n.55, 5330−5334.
51. Bakker A.B.H., Phillips J.H., Figdor C.J. and Lanier L.L., „Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, y§ T cells, and Antigen-specific CTL“, J. Immunol., 1998, 160, 5239−5245.
52. Walker P.R., Saas P., and Dietrich P.Y., „Tumor expression of FAS ligand (CD95) and the consequences“, Current Opinion in Immunology, 1998, n.10, 564−572.
53. Wagelie-Steffen A.L., Hartmann K., Vliagoftis H., Metcalfe D.D., „Fas ligand (FASL, CD95L, APO-1L) expression in murine mast cells“, J. Immunol., 1998, n.94, 569−574.
54. Liu Q.Y., Rubin M.A., Omene C., Lederman S., and Stein C., „Fas Ligand is constitutively secreted by prostate cancer cells in vitro“, Clinical Cancer Res., 1998, July, v. 4, 1803−1811.
55. Hahne M., Rimoldi D., Schroter M., Romeo P., Schreier M, French L, Schneider P, Bornand T., Fontana A., Lienard D. et al., „Melanoma cell expression of FAS (APO-1/CD95) ligand: implication for tumor immune escape“, Science, 1996, n.274, 1363−1366.
56. Cardi G., Heaney J.A., Schned A.R., and Ernstoff M.S., „Expression of FAS (APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma“, Cancer Res., 1998, May, n.58, 2078−2080.
57. Arai H., Gordon D., Nabel E.G., Nabel G.J., „Gene transfer of FAS ligand induces tumor regression in vivo“, Proc. Natl. Acad. Sci. USA, 1997, n.94, 13 862−13 867.
58. Seino K.I., Kayagaki N., Okumura K., Yagita H., „Antitumor effect of locally produced CD95 ligand“, Nat. Med., 1997, n.3, 165−170.
59. Wyllie A.H., Kerr J.F., Currie A.R., „Cell death: the significance of apoptosis“, Int. Rev. Cytol., 1980, v.69, 251−306.
60. Kerr J.F., Wyllie A.H., Currie A.R., „Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics“, Brit. J. Cancer, 1972, v.26, 239−257.
61. Blischenko E. Yu., Mirkina I. I., Mernenko O. A., Yatskin O. N., Satpaev
62. D.K., Strizhkov B.N. and Karelin A. A., „Cytotoxic activity of acetilcholine receptor ligands“, Biochemistry and Molecular Biology International, 1997, July, v.42. n. 4, 739−747.
63. Mernenko O.A., Blishchenko E.Y., Mirkina 1.1., Karelin A.A., „Met-enkephalin induces cytolytic processes of apoptotic type in K562 human erythroid leukemia cells“, FEBS Letters, 1996, n.383, 230−232.
64. Revillard J.P., Adorini L., Goldman M., Kabelitz D. and Waldmann H., „Apoptosis: potential for disease therapies“, Trends in Immunology, 1998, July, v.19, n.7, 291−293.
65. Golstein P., Ojcius D. M., Young J.D.-E., „Cell death mechanism and the immune system“, J. Immunol. Rev., 1991, n. 121, 29−65.
66. Warren H.S. and Smyth M.J., „NK cells and apoptosis“, Immunology and Cell Biology, 1999, n. 77, 64−75.
67. Griffith T.S. and Lynch D. H., „TRAIL: a molecule with multiple receptors and control mechanisms“, Current Opinion in Immunology, 1998, n. 10, 559−563.
68. Sashchenko L.P., Lukyanova T.I., Kabanova O.D., Mirkina I.I., Yatskin O.N., Pongor S., Gnuchev N.V., „Different pathways of the release of cytotoxic proteins in LAK cells“, Immunol.Lett., v.53, 1996, 25−29.
69. Mirkina I. I., Mernenko 0. A., Satpaev D. K., Karelin A.A., Blishchenko
70. E. Yu., „Cytolytic processes induced by TNF in L929 and K562 differ in DNA fragmentation mechanisms“, Immunol. Letters, 1996, n.52, 105−108.
71. Zhai Y., Guo R, Hsu T. L., Yu G. L., Ni J., „LIGHT, a novel ligand for lymphotoxinp receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer“, J. Clin. Invest., 1998, September, v.102, n.6, 1142−1151.
72. Blischenko E. Y. and Karelin A. A., „Tubocurarin induces the wide spectrum of cytolytic effects in tumor cells“, Immunology Letters, 1994, n. 42, 13−17.
73. Cohen J.J., Duke R.C., „Glucocorticoid activation of calciumdependent endonuclease in thymocyte nuclei leads to cell death“, J. Immunol., 1984, v.132, 38−43.
74. Wyllie A.H., Morris R.G., Smith A.L., Dunlop D., „Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependance on macromolecular synthesis“, J. Pathol., 1984, v. 142, 67−77.
75. Zhivotovsky B., Wade D., Gahm A., Orrenius S., Nicotera P.L., „Formation of 50 kb chromatin fragments isolated liver nuclei is mediated by protease and endonuclease activation“, FEBS Lett., 1994, v.351,150−154.
76. Bortner C.D., Oldenburg N.B.E., Cidlowski J.A., „The role of DNA fragmentation in apoptosis“, Trends in Cell Biology, 1995, v.5, 21−26.
77. Razin S.V., Hancock R., Iarovaia O., Westergaard O., Gromova I., Georgiev G.P., „Structural-functional organisation of chromosomal DNA domains“, Cold Spring Harbor Symposia on Quantative Biology, 58, 1993, 2535.
78. Schulzeosthoff K., Walczak H., Droge W., Krammer P.H., „Cell nucleus and DNA fragmentation are not required for apoptosis“, J. Cell Biol., 1994, v.127, 15−20.
79. Yonehara S., Ishii A., Yonehara M., „A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen codownregulated with the receptor of tumor necrosis factor“, J. Exp. Med., 1989, v.169, 1747−1756.
80. Trauth B. C., Klas C., Peters A. M., Matzku S., Moller P., Falk W., Debatin K.M., Krammer P.H., „Monoclonal antibody-mediated tumor regression by induction of apoptosis“, Science, 1989, v.245, 301−305.
81. Boldin M. P., Varfolomeev E. E., Pancer Z., Mett I. L., Camonis J. H., Wallach D., „A novel protein that interacts with the death domain of FAS/APOl contains a sequence motif related to the death domain“, J. Biol. Chem, 1995, v.270, 7795−7798.
82. Peter M.E. and Krammer P.H., „Mechanisms of CD95 (AP0−1/FAS)-mediated apoptosis“, Current Opinion in Immunology, 1998, 10, 545−551.
83. Tschopp J., Irmler M. and Thome M., „Inhibition of FAS death signal by FLIPs“, Current Opinion in Immunology, 1998, n.10, 552−558.
84. Hsu H., Shu H. B., Pan M. G., Goeddel D.V., „TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways“, Cell, 1996, n. 84, 299−308.
85. Hsu H., Shu H.B., Baichwal V., Goeddel D.V., „TNF- dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex“, Immunity, 1996, n.4, 387−396.
86. Liu Z.G., Hsu H., Goeddel D.V., Karin M., „Dissection of TNF receptor 1 effector function: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death“, Cell, 1996, n. 87, 565−576.
87. Beg A. A., Baltimore D., „An essential role for NF-kappaB in preventing TNF-alpha-induced cell death“, Science, 1996, 274, 782−784.
88. Van Antwerp D.J., Martin S., Kafri T., Green D.R., Verma I.M., „Suppression of TNFa-induced apoptosis by NF-kB“, Science, 1996, 274, 787−789.
89. Ellis R. M., Horvitz H. R., „Genetic control of programmed cell death in the nematode C. elegans“, Cell, 1986, v. 44, 817−829.
90. Yuan J., Shaham S., Ledoux S., Ellis H.M., Horvitz H. R., » The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 (3 converting enzyme", Cell, 1993, v.75, 641−652.
91. Ceretti D. P., Kozlosky C.J., Mosley B., Nelson N., Ness K. V., Greebstreet T. A., March C. J., Kronheim S. R., Druch T., «Molecular cloning of the interleukin-1 p converting enzyme», Science, 1992, v. 256, 97 100.
92. Miura M., Zhu H., Rotello R., Hartweig E. A., Yuan J., «Induction of apoptosis in fibroblasts by IL-1 p converting enzyme, a mammalian homologue of the C. elegans cell death gene ced-3″, Cell, 1993, v. 75, 653−660.
93. Cryns V. and Yuan J., „Proteases to die for“, Genes & Development, 12, 1551−1570.
94. Alnemri E. S., Livingston D. J., Nicholson D. W., Salvesen G., Thornberry N. A., Wong W. W. and Yuan J., 1996, „Human ICE/CED-3 protease nomenclature“, Cell, 87, 171.
95. Boldin M. P., Goncharov T. M., Goltsev Y. V., Wallach D., „Involvement of MACH, a novel MORTl/FADD-interacting protease, in Fas/APO-1- and TNF-receptor-induced cell death“, Cell, 1996, 85, 803−815.
96. Enari M., Talanian R. V., Wong W. W., Nagata S., „Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis“, Nature, 1996, 380, 723−726.
97. Fernandes-Alnemri T., Armstrong R. C., Krebs J., Srinivasula S. M., et al., „In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains“, Proc. Natl. Acad. Sci. USA, 1996, 93, 7464−7469.
98. Bossy-Wetzel E., Newmeyer D.D., and Green D.R., „Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspaseactivation and independently of mitochondrial transmembrane depolarization“, EMBO J., 1998, 17, 37−49.
99. Chauhan D., Pandey P., Ogata A., Teoh N., Krett N., Halgren R., Rosen S., Kufe D., Kharbanda S., and Anderson K., „Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells“, J. Biol. Chem., 1997, 272, 29 995−29 997.
100. Caulin C., Salvesen G.S., and Oshima R.G., „Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis“, J. Cell. Biol., 1997, 1379−1394.
101. Zhivotovsky B., Gahm A., Orrenius S., » Two different proteases are involved in the proteolysis of lamin during apoptosis", Biochem. Biophys. Res. Commun, 1997, April 7, 233 (1), 96−101.
102. Rao L., Perez D., White E., «Lamin proteolysis facilitates nuclear events during apoptosis», J. Cell Biol. 1996, n. 135, 1441−1455.
103. Bojes H.K., Feng X., Kehrer J.P., Cohen G.M., «Apoptosis in hematopoietic cells (FL5.12) caused by interleukin-3 withdrawal: relationship to caspase activity and the loss of glutathione», Cell Death Differ., 1999 January 6 (1), 61−70.
104. Sabol S.L., Li R., Lee T.Y., Abdul-Khalek R., «Inhibition of apoptosis-associated DNA fragmentation activity in nonapoptotic cells: the role of DNA fragmentation factor-45″, Biochem Biophys Res Commun., 1998, December 9, 253 (1), 151−158.
105. Sakahira H., „Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis“, Nature, 1998, January 1- 391(6662), 96−99.
106. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S., „A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD“, Nature, 1998, Jan 1- 391 (6662), 43−50.
107. Ekert P.G., Silke J., Vaux D.L., „Inhibition of apoptosis and clonogenic survival of cells expressing crmA variants: optimal caspase substrates are not necessarily optimal inhibitors“, EMBO J., 1999, January 15, 18(2), 330−338.
108. Fisher A.J., Cruz W., Zoog S.J., Schneider C. L., Friesen P.D., „Crystal structure of baculovirus P35: role of a novel reactive site loop in apoptotic caspase inhibition“, EMBO J., 1999, April 15, 18 (8), 2031−2039.
109. Deveraux Q. L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., „IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases“, EMBO J., 1998, v.17, n.8, 2215−2223.
110. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S.,
111. NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAPl and c-IAP2 to suppress caspase-8 activation», Science, 1998, v.281, September 11, 1680−1683
112. Jaattela M., «Escaping cell death: survival proteins in cancer», Exp. Cell. Res., 1999, Apr 10, 248 (1), 30−43.
113. Chen P., Tian J., Kovesdi I., Bruder J.T., " Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis", J. Biol. Chem., 1998, 273, 5815−5820.
114. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., «Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors», Nature, 1997, April 3, v.386, 517−521.
115. Irmler M., Thome M., Hahne M., Schneired P., Hofmann K., Steiner V., Bordmer J.L., Schroter M., «Inhibition of death receptor signals by cellular FLIP», Nature, 1997, 388, 190−195.
116. Lenardo M. J., «Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis», Nature, 1991, 3533, 858−861.
117. Tsujimoto Y., Finger L.R., Yunis J., Nowell P.C., Croce C.M., «Cloning of the chromosome breakpoint of neoplastic B cells the t(14−18) chromosome translocation», Science, 1984, v.226, 1097−1099.
118. Korsmeyer S.J. and Greenberg P.D., «Cancer: Tuning in on death programs», Current Opinion in Immunology, 1998, 10, 543−544.
119. Favrot M., Coll J.L., Louis N. and Negoescu A., «Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy», Gene Therapy, 1998, n. 5, 728−739.
120. Sedlak T.W., Oltvai Z.N., Yang E., Wang K., Boise L.H., Thompson C.B., Korsmeyer S.J." Multiple Bcl-2 family members demonstrate selective dimerization with Bax", Proc. Natl. Acad. Sci. USA, 1995, 92, 7834−7838.
121. Jurgensmeier J.M., Xie Z., Deveraux Q., Ellerby L., Bredesen D., Reed J.C., «Bax directly induces release of cytochrome c from isolated mitochondria», Proc. Natl. Acad. Sci. USA, 1998, 95, 4997−5002.
122. Li H., Zhu H., Xu C. J., Yuan J., «Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis», Cell, 1998, August 21, 94 (4), 491−501.
123. Kiselev S. L., Kustikova 0. S., Korobko E.V., Prokhortchouk E.B., Kabishev A. A., Lukanidin E.M., and Georgiev G.P., «Molecular Cloning and Characterization of the mouse tag! gene encoding a novel cytokine», JBC, 1998, v.273, n.29, 18 633−18 639.
124. Kang D., Liu G., Lundstrom E. C., and Steiner H., «A peptidoglycan recognition protein in innate immunity conserved from insects to humans», Proc. Natl. Acad. Sci., USA., 1998, August, v.95, 10 078−10 082.
125. Maniatis T., Fritsch E. F., Sambrook J., J. Molecular cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1982.
126. Ausubel F. M., Brent R., Kingston R. E., Moore D.D., " Short protocols in molecular biology: a compendium of methods from Current protocols on molecular biology", 1989.
127. Titus D. E., «Promega Protocols and Applications Guide», second edition, March, 1991.
128. Amersham International pic: Membrane transfer and detection methods, Amersham UK, 1991.
129. Stratagene: ZAP Express cDNA Synthesis Kit and ZAP Express cDNA Gigapack III Gold Cloning Kit, Instruction manual.
130. Holbrook N. J., Smith K. A., Fornace A.J., Comeau C.M., Wiskocil R.L. & Crabtree G.R., «T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells», Proc. Natl. Acad. Sci. USA, 1984, v. 81, 1634−1638.
131. Ojcius D. M., Zychlinsky A. and Young J.D.E., Ionophore-induced apoptosis: role of DNA fragmentation and calcium fluxes", Exp. Cell Research, 1991, 197, 43−49.
132. Heider K.H., Dammrich J., Sktoch-Angel P., Hermelink H.K., «Differential expression of CD44 splice variants in intestinal and diffuse type human gastric adenocarcinoma and normal gastric mucosa», Cancer Res. 53, 1993, 4197−4203.
133. Laemmli, U.K.Nature.1970, v.221, 680.
134. Ochiai M., Ashida M., «A pattern recognition protein for peptidoglican. Cloning the cDNA and the gene of the silkworm, Bombyx mori», J. Biol. Chem., 1999, April 23, 274 (17), 11 854−11 858.
135. Lawton P., Nelson J., Tizard R., and Browning J.L., «Characterization of the mouse lymphotoxin-(3 gene», J. Immunol., 1995, 154, 239−246.
136. Lee R.K., Spielman J., Zhao D.Y., Olsen K. J., Podack E. R., «Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells», J. Immunol., 1996 September, 157 (5), 1919−1925.
137. Ueno M., Yahara I., Kishi K., «Isolation and partial characterization of cytoplasmic granules of LAK cells from mice showing side effects of recombinant human IL-2», Fundam. Appl. Toxicol. 1997, Mar. 36 (1), 39−46.
138. Warren H.S. and Smyth M.J., «NK cells and apoptosis», Immunology and Cell Biology, 1999, 77, 64−75.